Summary

• Over the quarter, the BlackRock Health Sciences Term Trust increased its exposure to pharmaceuticals and biotechnology firms.
• Within the pharmaceuticals subsector, the Trust initiated positions in GSK and Vertex Pharmaceuticals, due to positive fundamentals and progress in a rare disease program, respectively.
• Elsewhere, the Trust reduced its exposure to medical devices & supplies companies, which included locking in profits.

Highlights

1

8.1% *

Distribution Rate

2

7.9% **

1 year Market Price Return Annualized

3

13.4% ***

Private Exposure

Contents

• Performance overview
• Portfolio statistics
• Private investments

Quarterly Snapshot

All information is as of